Secikinumab

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions

Axial Spondylarthritis (axSpA)PsoriasisSecukinumab

Unknown Phase

A Registry of Patients With Moderate to Severe Plaque Psoriasis

CompletedNCT02786186

Novartis PharmaceuticalsPsoriasis

Start: 2015-12-23End: 2026-01-22Updated: 2026-02-19

Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis

CompletedNCT07130331

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAxial Spondylarthritis (axSpA), Secukinumab

Start: 2020-06-01End: 2025-08-01Updated: 2025-08-19

Related Papers

Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry.

2026-07-21

Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.

2022-12-104 citations

Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.

2019-06-218 citations